| Literature DB >> 29403914 |
Bokka Ramesh1, Nemali Manjula1, Sistla Ramakrishna2, Potturi Sita Devi1.
Abstract
A novel bioanalytical method was developed and validated for the quantitative determination of darunavir (DRV) in rat plasma by employing hydrophilic interaction chromatography and tandem mass spectrometry (HILIC-MS/MS) with supported liquid extraction (SLE). Irbesartan (IRB) was used as an internal standard (IS). The analyte in rat plasma (200 µL) was isolated through SLE using ethyl acetate as the eluting solvent. The chromatographic separation was achieved on Luna-HILIC (250 mm×4.6 mm, 5 μm) column with a mobile phase of 0.1% of formic acid in water:acetonitrile (5: 95, v/v), at a constant flow rate of 1.0 mL/min. The MS/MS ion transitions for DRV (548.1→392.0) and IS (429.2→207.1) were monitored on an ion trap mass spectrometer, operating in the multiple reaction monitoring (MRM) mode. The lower limit of quantitation (LLOQ) was 0.2 ng/mL and quantitation range was 0.2-5000 ng/mL. The method was validated for its selectivity, sensitivity, carryover, linearity, precision, accuracy, recovery, matrix effect and stability. The method was successfully applied to pharmacokinetic study in rats.Entities:
Keywords: Darunavir; HILIC–MS/MS; Rat plasma; Supported liquid extraction
Year: 2014 PMID: 29403914 PMCID: PMC5761474 DOI: 10.1016/j.jpha.2014.05.001
Source DB: PubMed Journal: J Pharm Anal ISSN: 2214-0883
Fig. 1(A) ESI-MS signal at different portions of ACN in mobile phase and (B) effect of different solvent types on the extraction efficiency.
Fig. 2Product ion mass spectra of (A) DRV (m/z 548.1→392.0, scan range 100–700 amu) and (B) IS (m/z 429.3→207.0, scan range 50–500 amu) in positive ion mode.
Fig. 3Effects of acetonitrile content in the mobile phase on DRV (100 ng/mL) retention time on the HILIC column.
Fig. 4Representative MRM chromatograms of (A) blank rat plasma, (B) rat plasma spiked with 0.2 ng/mL (LLOQ) DRV, 50 ng/mL IS and (C) a rat plasma sample obtained 1.5 h after an intravenous administration of DRV.
Intra- and inter-day precision and accuracy for the detection of DRV in rat plasma.
| Analyte | Spiked concentration (ng/mL) | Intra-day ( | Inter-day ( | ||||
|---|---|---|---|---|---|---|---|
| Mean (ng/mL) | Accuracy (%) | CV (%) | Mean (ng/mL) | Accuracy (%) | CV (%) | ||
| DRV | 0.2 | 0.19 | 95.0 | 5.27 | 0.21 | 105.0 | 4.71 |
| 3.0 | 3.12 | 104.0 | 6.84 | 3.23 | 107.6 | 8.66 | |
| 2500.0 | 2543.13 | 101.7 | 0.43 | 2552.05 | 102.0 | 0.53 | |
| 4000.0 | 4063.08 | 101.5 | 0.38 | 4074.14 | 101.8 | 0.59 | |
The recovery and matrix effect of DRV and IS (n=6).
| Analyte | Concentration (ng/mL) | Recovery (%) | Matrix effect (%) | ||
|---|---|---|---|---|---|
| Mean±SD | RSD (%) | Mean±SD | RSD (%) | ||
| DRV | 3 | 95.27±2.52 | 2.65 | 94.13±2.54 | 2.68 |
| 2500 | 96.42±2.19 | 2.28 | 95.56±4.01 | 4.17 | |
| 4000 | 94.16±1.34 | 1.42 | 96.81±3.51 | 3.64 | |
| IS | 50 | 92.13±1.84 | 1.99 | 93.16±3.87 | 4.16 |
Stability of DRV in rat plasma (n=6).
| Stability tested | Concentration added (ng/mL) | Concentration found (ng/mL) | Precision (RSD, %) | Accuracy (RE, %) |
| Autosampler stability (at 10 °C for 24 h) | 3.0 | 2.95±0.11 | 3.72 | −3.33 |
| 3000.0 | 3025.13±3.21 | 1.28 | 1.25 | |
| Bench-top stability (5 h at room temperature) | 3.0 | 3.35±0.05 | 8.47 | −1.66 |
| 3000.0 | 3013.24±3.58 | 0.88 | 0.75 | |
| Freeze–thaw stability (three cycles) | 3.0 | 3.18±0.04 | 6.34 | 5.00 |
| 3000.0 | 3020.17±2.89 | 0.71 | 1.00 | |
| Long-term stability (at −70 °C for 50 days) | 3.0 | 2.98±0.03 | 4.68 | 6.60 |
| 3000.0 | 2994.3±4.24 | 1.05 | 0.75 | |
Fig. 5Mean plasma concentration–time profile of DRV after an oral 50 mg/kg dose of DRV to male Wistar rats.
Pharmacokinetic parameters of DRV after oral administration at a dose of 50 mg/kg to rats (n=6).
| Pharmacokinetic parameters | Mean±SD |
|---|---|
| 130±4 | |
| 3.00±0.28 | |
| 5.31±0.71 | |
| AUC0− | 1014±48 |
| AUMC0− | 6518±386 |
| AUC0− | 1064±49 |
| AUMC0− | 8408±914 |
| MRT0− | 7.89±0.83 |